Publications by authors named "Mark Morrow"

Claim this Profile
I
Ischemic Optic Neuropathy.
Mark J Morrow

Continuum (Minneap Minn)· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recurrent Chemical Meningitis Due to Parasellar Epidermoid Cyst.
Bhavesh Trikamji, Mark Morrow

Cureus· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Why Therapeutic Compliance in Optic Neuritis Deserves to Be More Than Just a Footnote: Response.
Mark Morrow

J Neuroophthalmol· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Should Oral Corticosteroids Be Used to Treat Demyelinating Optic Neuritis?
Mark J Morrow, Melissa W Ko

J Neuroophthalmol· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multiple sclerosis: review of eye movement disorders and update of disease-modifying therapies.
Lilyana Amezcua, Mark J Morrow, Guy V Jirawuthiworavong

Curr Opin Ophthalmol· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Re-evaluating the treatment of acute optic neuritis.
Jeffrey L Bennett, Molly Nickerson, Fiona Costello, Robert C Sergott, Jonathan C Calkwood, Mark Morrow

J Neurol Neurosurg Psychiatry· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neuromyelitis optica.
Mark J Morrow, Dean Wingerchuk

J Neuroophthalmol· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I safety, pharmacokinetic, and pharmacodynamic study of ENMD-2076, a novel angiogenic and Aurora kinase inhibitor, in patients with advanced solid tumors.
Jennifer R Diamond, Bruno R Bastos, Ryan J Hansen, Daniel L Gustafson, S Gail Eckhardt, Mark Morrow

Clin Cancer Res· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthetic routes to pyrrolizine-1,5-dione derivatives by flash vacuum pyrolysis of amidomethylene derivatives of Meldrum's acid.
Hamish McNab, Mark Morrow, Simon Parsons, David A Shannon, Kirsti Withell

Org Biomol Chem· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I study of bortezomib, etoposide and carboplatin in patients with advanced solid tumors refractory to standard therapy.
Christopher Lieu, Laura Chow, A Scott Pierson, S Gail Eckhardt, Cindy L O'Bryant, Mark Morrow

Invest New Drugs· February 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vorinostat and bortezomib exert synergistic antiproliferative and proapoptotic effects in colon cancer cell models.
Todd M Pitts, Mark Morrow, Sara A Kaufman, John J Tentler, S Gail Eckhardt

Mol Cancer Ther· February 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I pharmacological and biological study of PI-88 and docetaxel in patients with advanced malignancies.
Laura Q M Chow, Daniel L Gustafson, Cindy L O'Bryant, Lia Gore, Michele Basche, Mark C Morrow

Cancer Chemother Pharmacol· December 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I safety, pharmacological, and biological study of the farnesyl protein transferase inhibitor, lonafarnib (SCH 663366), in combination with cisplatin and gemcitabine in patients with advanced solid tumors.
Laura Q M Chow, S Gail Eckhardt, Cindy L O'Bryant, Mary Kay Schultz, Mark Morrow

Cancer Chemother Pharmacol· September 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Investigation of two dosing schedules of vandetanib (ZD6474), an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, in combination with irinotecan in a human colon cancer xenograft model.
Teresa Troiani, Natalie J Serkova, Daniel L Gustafson, Thomas K Henthorn, Owen Lockerbie, Mark Morrow

Clin Cancer Res· November 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I biological and pharmacologic study of the heparanase inhibitor PI-88 in patients with advanced solid tumors.
Michele Basche, Daniel L Gustafson, Scott N Holden, Cindy L O'Bryant, Lia Gore, Mark Morrow

Clin Cancer Res· September 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sequence-dependent inhibition of human colon cancer cell growth and of prosurvival pathways by oxaliplatin in combination with ZD6474 (Zactima), an inhibitor of VEGFR and EGFR tyrosine kinases.
Teresa Troiani, Owen Lockerbie, Mark Morrow, Fortunato Ciardiello, S Gail Eckhardt

Mol Cancer Ther· July 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II trial of bevacizumab in combination with weekly docetaxel in metastatic breast cancer patients.
Bhuvaneswari Ramaswamy, Anthony D Elias, Nicole T Kelbick, Angela Dodley, Mark Morrow

Clin Cancer Res· May 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis